Clinical Trial Update: Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the efficacy and safety of Biphasic Insulin Aspart 30 in adults with Type 1 or Type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Biphasic insulin aspart 30 (insulin aspart, biphasic 30/70)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 1 | Phase 3 | Status: COMPLETED